ChabiotechLtd Balance Sheet Health
Financial Health criteria checks 3/6
ChabiotechLtd has a total shareholder equity of ₩768.8B and total debt of ₩596.8B, which brings its debt-to-equity ratio to 77.6%. Its total assets and total liabilities are ₩2,070.1B and ₩1,301.3B respectively.
Key information
77.6%
Debt to equity ratio
₩596.84b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩276.77b |
| Equity | ₩768.80b |
| Total liabilities | ₩1.30t |
| Total assets | ₩2.07t |
Recent financial health updates
Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?
Nov 12
Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?
Mar 01Recent updates
Is ChabiotechLtd (KOSDAQ:085660) Using Too Much Debt?
Nov 12Chabiotech Co.,Ltd.'s (KOSDAQ:085660) Shares Lagging The Industry But So Is The Business
Aug 07Is CHA Biotech (KOSDAQ:085660) Using Too Much Debt?
Mar 01If You Had Bought CHA Biotech's (KOSDAQ:085660) Shares Three Years Ago You Would Be Down 52%
Jan 25The Trends At CHA Biotech (KOSDAQ:085660) That You Should Know About
Dec 21Financial Position Analysis
Short Term Liabilities: A085660's short term assets (₩652.2B) do not cover its short term liabilities (₩936.4B).
Long Term Liabilities: A085660's short term assets (₩652.2B) exceed its long term liabilities (₩365.0B).
Debt to Equity History and Analysis
Debt Level: A085660's net debt to equity ratio (41.6%) is considered high.
Reducing Debt: A085660's debt to equity ratio has increased from 28.1% to 77.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A085660 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A085660 has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 18.4% each year.